BioNTech SE announced that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as a Board Director at affiliated companies of the BioNTech Group by mutual agreement to pursue new professional opportunities. The process of transitioning his responsibilities to other members of the Management Board is underway, ensuring a smooth handover.
Ryan Richardson joined BioNTech in 2018 and has served as Chief Strategy Officer since January 2020. During his time at the Company, he contributed significantly to BioNTech’s successful development, including its Series B financing, the Initial Public Offering on Nasdaq, and subsequent private placement and follow-on equity financings, which together raised more than USD 1 billion in capital. In addition to building Global Strategy and Corporate Development functions which supported BioNTech’s global expansion and the execution of more than a dozen collaborations and acquisitions, Ryan Richardson held responsibility for Capital Markets and Investor Relations functions, during which time BioNTech expanded its analyst coverage and strengthened its global shareholder base. He has served on the Board of Directors of BioNTech’s wholly owned subsidiary InstaDeep Ltd. (“InstaDeep”), a leading global technology company in the field of AI and machine learning, since the acquisition in 2023.
“On behalf of the entire Supervisory Board, I would like to thank Ryan for his commitment and what he has achieved for BioNTech since 2018. Ryan played a key role in BioNTech’s transition from a private clinical-stage biotech to a publicly listed, fully integrated biotechnology company,” said Helmut Jeggle, Chairman of the Supervisory Board. “Today, BioNTech is well-positioned to establish the next wave of innovations and transform into a multi-product company. We wish Ryan all the best for his future and look forward to seeing his continued success.”
“I am both humbled and incredibly proud of what we have accomplished over the last seven years. BioNTech has become one of the largest global biotechnology companies with a unique portfolio of novel product candidates, a strong balance sheet, and distinctive innovation capabilities,” said Ryan Richardson, Chief Strategy Officer at BioNTech. “I believe BioNTech is entering an exciting new period and is on a trajectory to become a multi-product company, fulfilling its mission of bringing new therapies to cancer patients. I wish the Company and my colleagues all the best and every success in the future.”
“From our IPO to strategic acquisitions, Ryan’s valued impact can be seen across many of BioNTech’s key achievements over the past years,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “He departs with our appreciation for his service during a pivotal period of growth. On behalf of the Management Board, I wish him all the best as he embarks on the next chapter in his career.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!